| Name | Title | Contact Details |
|---|
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns` programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. Terns` investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.
Odyssey Behavioral Health consists of a growing portfolio of quality behavioral health facilities with evidence-based clinical care.
Dyancon is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Chemrx is a South Plainfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.